Certolizumab Pegol for the Treatment of Chronic Plague Psoriasis: DLQI and WPAI Patient-Reported Outcomes From an Ongoing Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT)

Vincent Piguet,¹ Andrew Blauvelt,² Daniel Burge,³ Luke Peterson,⁴ Janice Drew,³ Robert Rolleri,⁴ Jolanta Węgłowska⁵

¹Cardiff University and University Hospital of Wales, Cardiff, UK, ²Oregon Medical Research Center, Portland, OR; ³Dermira, Inc., Menlo Park, CA; ⁴UCB BioSciences, Inc., Raleigh, NC; ⁴Niepubliczny Zakład Opieki Zdrowotnej multiMedica, Wrocław, Poland

INTRODUCTION

Psoriasis affects ~3% of adults in the US^{1,2} and ~2-6% of adults in Europe¹; onset can begin at any age, though most patients develop the disease in the third decade of liffe⁴

Psoriasis can have a significant negative impact on the physical, emotional, psychosocial, and economic well-being of affected patients^{5,6}

- In the US, over 80% of psoriasis patients report that the disease negatively affects their emotional state and their enjoyment of life⁶ Over 90% of unemployed US psoriasis natients report not working solely due to psoriasis
- or portion of alternative to spontasis patients report not working solely due to portional or psortable arthritis, and almost half of working psortasis patients regularly miss work due to the disease⁶
- Quality of life instruments for psoriasis have been useful to assess the impact of psoriasis on patients lives and well-being^{7,0}

 Certolizumab pegol (CZP) is the only PEGylated, Fc-free, anti-TNF biologic and is currently under investigation for the treatment of moderate-to-severe chronic plaque psoriasis Previously presented data through Week 16 of 3 ongoing, randomized, double-blind, placebo-controlled trials have demonstrated clinically meaningful efficacy and a safety profile consistent with anti-TNF therapy®10

CIMPACT (NCT02346240) is designed to assess the efficacy and safety of treatment with CZP compared with placebo and etanercept (ETN) in adult patients with moderate-to-severe chronic plaque psoriasis; results of patient-reported outcomes through

Week 16 for all patients and results through Week 48 for patients initially treated with CZF

METHODS

Study Design

CIMPACT is an ongoing phase 3, randomized, multinational, parallel-group, placebo- and active-controlled trial

Patients were randomized 3:3:1:3 to CZP 400 mg every 2 weeks (Q2W), CZP 200 mg Q2W (after an initial loading dose of 400 mg at Weeks 0, 2 and 4), or placebo Q2W for 16 weeks of ETN twice weekly for 12 weeks (Figure 1)

 At Week 16. CZP- and ETN-treated PASI 75 responders were re-randomized and continued for 32 weeks of maintenance treatment:


 From CZP 400 mg Q2W to 400 mg Q2W. 200 mg Q2W, or placebo Q2W From CZP 200 mg Q2W to 400 mg every 4 weeks (Q4W), 200 mg Q2W, or placebo

From ETN to CZP 200 mg Q2W (after loading dose) or placebo Q2W

 At Week 16, placebo-treated PASI 75 responders continued placebo Q2W for 32 weeks of ntenance treatment

At Week 16, PASI 75 nonresponders entered an Escape Arm for treatment with CZP 400 mg Q2W

Figure 1. Study Design



Patients

Eligible patients were ≥18 years of age, had moderate-to-severe chronic plaque psoriasis for ≥ 6 months with a Baseline psoriasis area and severity index (PASI) ≥ 12 , affected body surface area (BSA) $\geq 10\%$, and physician's global assessment (PGA; 5-point scale) ≥ 3 Patients had to be candidates for systemic psoriasis therapy, phototherapy, and/or photochemotherapy

protoclemoneapy Patients were excluded if they had erythrodermic, guttate, or generalized pustular forms of porsiasis, previous treatment with CZP, ETN, or >2 biologics (including anti-TNF); or history of primary failure to any biologic or secondary failure to >1 biologic

Patient-Reported Outcome Measures and Study Assessments Dermatology Life Quality Index (DLQI)

- Validated, skin disease-specific questionnaire that assesses how disease symptoms/treatment affect patient health-related quality of life; higher scores indicate lower quality of life (numeric rating scale 0 to 30)
- · Work Productivity and Activity Impairment-Specific Health Problem questionnaire (WPAI) 6-item, self-reported survey that covers 4 domains of work/daily activity impairment.
- including:
- 1. Absenteeism (work time missed) 2. Presenteeism (reduced on-the-iob effectiveness)
- 3. Work productivity loss (overall work impairment)
- 4. Activity impairment (impairment performing regular daily activities) Questions related to the first 3 domains were to be completed only by patients who were employed at the time of the assessment; questions related to the last domain were to be
- pleted by all patients WPAI domain scores are impairment percentages: higher numbers indicate greater impairment and less productivity
- · Assessments at Weeks 16 and 48
- Change from Baseline (CfB) in DLQI
- DLQI minimal clinically important difference (MCID; ≥4-point reduction⁷) responder rate
- DLQI 0/1 (absolute score ≤1) responder rate CfB in WPAI

Statistical Analysis

- Efficacy analyses at Week 16 were performed on the Randomized Set (all randomized patients) Efficacy analyses at Week 48 were performed on the Maintenance Set (patients completing
- Encady analyses at week to were performed on the wainlenance set (patients comp the Week 16 visit with 21 efficacy measurement during the Maintenance Period)
 Inferential statistics for CfB in DLQI and WPAI at Week 16 were based on analysis of
- covariance (ANCOVA) Mean CfB values are presented for continuous variables, and percentages are presented


for responder variables · Last observation carried forward (LOCF) imputation was used to impute data for CfB in

DLQI (Week 16 and 48) and WPAI (Week 16) Nonresponse imputation was used for DLQI MCID and DLQI 0/1 analyses

· Week 48 WPAI data was assessed based on observed cases

RESULTS

Patient Disposition, Demographics, and Baseline Characteristics A total of 167, 165, and 57 patients were randomized to CZP 400 mg Q2W, CZP 200 mg Q2W, or placebo, respectively (Figure 2) Patient demographics and Baseline characteristics were similar between groups (Table 1)



CZP 400 mg Q4W; BW, twice area and severity index; Q2W, ey

	Placebo (N=57)	CZP 200 mg Q2W (N=165)	CZP 400 mg Q2W (N=167)
Demographics		(14-100)	(10-107)
Age (years), mean ± SD	46.5 ± 12.5	46.7 ± 13.5	45.4 ± 12.4
Male, n (%)	34 (59.6)	113 (68.5)	107 (64.1)
White, n (%)	57 (100)	158 (95.8)	162 (97.0)
Employed, n (%)	49 (86.0)	117 (70.9)	123 (73.7)
Geographic Region, n (%) North America Central/Eastern Europe Western Europe	10 (17.5) 36 (63.2) 11 (19.3)	26 (15.8) 107 (64.8) 32 (19.4)	27 (16.2) 109 (65.3) 31 (18.6)
Weight (kg) Mean ± SD Range	93.7 ± 29.7 55.0 - 198.5	89.7 ± 20.6 49.0 - 171.1	86.3 ± 20.0 41.8 - 152.0
BMI (kg/m²) Mean ± SD Range	31.2 ± 8.5 19.6 - 57.4	29.8 ± 6.1 18.3 - 53.0	28.9 ± 5.9 15.4 - 45.1
Baseline disease characteristic	s		
Duration of psoriasis at screening (years) Mean ± SD Range	18.9 ± 12.9 0.8 - 54.6	19.5 ± 13.2 0.5 - 63.7	17.8 ± 11.5 0.5 - 56.9
Concurrent psoriatic arthritis, n (%)	12 (21.1)	27 (16.4)	24 (14.4)
PASI Mean ± SD Range	19.1 ± 7.1 12.0 - 43.1	21.4 ± 8.8 12.0 - 55.5	20.8 ± 7.7 12.0 - 58.5
BSA (%), mean ± SD	24.3 ± 13.8	28.1 ± 16.7	27.6 ± 15.3
PGA, n (%) 3: moderate 4: severe	40 (70.2) 17 (29.8)	114 (69.1) 51 (30.9)	113 (67.7) 54 (32.3)
Prior biologic use," n (%) anti-TNF anti-IL17	11 (19.3) 5 (8.8) 8 (14.0)	44 (26.7) 4 (2.4) 38 (23.0)	48 (28.7) 4 (2.4) 35 (21.0)
DLQI, mean ± SD	13.2 ± 7.6	12.8 ± 7.0	15.3 ± 7.3
WPAI domain scores, mean ± SD Absenteeism Presenteeism Work productivity loss Activity impairment	7.0 ± 24.1 18.4 ± 22.9 25.1 ± 29.7 26.1 ± 25.1	9.5 ± 24.9 21.1 ± 24.7 28.6 ± 31.2 29.8 ± 28.8	5.8 ± 16.6 28.4 ± 26.7 31.9 ± 29.5 35.1 ± 26.6


Patient-Reported Outcomes

Baseline to Week 16

At Week 16, patients treated with CZP 400 mg Q2W and CZP 200 mg Q2W demonstrated clinically meaningful improvements in DLQI vs placebo (Figure 3)

 At Week 16, CZP-treated patients demonstrated numerically greater improvement in both DLQI MCID (Figure 4A) and DLQI 0/1 (Figure 4B) responder rates compared with placebo-treated patients; the CZP 400 mg Q2W group had numerically greater improvement compared with the CZP 200 mg Q2W group

Figure 3. DLQI Mean Scores at Baseline and Week 16



"th=0.0001 vs placebo based on adjusted least squares mean difference from an ANCOW region, and prior biologic exposure (yea/ho) as factors and Baseline DLQ) score as a covar "CZP 200 mg CZW patients received a loading dose of CZP-400 mg at Weeks 0, 2, and 4 "If earlier did not here DLDI mean score values odel with treatment group, using LOCF imputation - persons use non-new output meth Stocher Webbi NCOVA, analysis of overlance; OB, change from Baseline; CZP; certolizumab pegol; DLQI, Dermatology Life Quality Index; LOCF, et alconomics and on socied featured. (OM: series). "Strategy and accounting and control of the series of

Figure 4. DLQI Minimal Clinically Important Difference^a and DLQI 0/1 Responder Rates at Week 16




energional imputation numab pegol; DLQI, Dermatology Life Quality Index; LOCF; last observation carried forward; Q2W, every 2 weeks CZP certoiz

Baseline to Week 48

 Better maintenance of response was observed at Week 48 for those patients re-randomized from CZP 400 mg Q2W or CZP 200 mg Q2W to either dose of CZP compared with placebo in DLQI (Figure 5A), DLQI MCID (Figure 5B), and DLQI 0/1 (Figure 5C); the greatest responses were noted in subjects treated with CZP 400 mg Q2W during both the Initial and Maintenance Periods





tation and no statistical comparisons were performed at Week 48 ology Quality of Life Index; LOCF; last observation carried forward; Q2W, every 2

WPAI Baseline to Week 16

· As assessed by WPAI, patients receiving either CZP dose had improvements in absenteeism, presenteeism, work productivity loss, and activity impairment at Week 16 (Figure 6): greater improvements were generally observed in subjects receiving CZP 400 mg Q2W

Raseline to Week 48


· Patients initially treated with CZP and re-randomized to the same or different dose of CZP maintained improvement across WPAI domains at Week 48 (Figure 7)



p-values are nominal and are based on adjusted least squares group, region, prior biologic exposure (yes/no) as factors and Ba

Weeks 0, 2, and 4 Ibservation carried forward; Q2W, every 2 weeks Usedth Deubleon

Figure 7. Mean Absolute Change from Baseline in WPAI Domain Scores at Week 48



CZP; certolizamab pept QZW, every 2 weeks; Q4W, every 4 weeks; WPAI, Work Productivity and Activi Durationneise. Service Health Drivlem

CONCLUSIONS

- In the Initial Treatment Period, CZP-treated patients had clinically meaningful improvements in DLQI, with a greater proportion of subjects achieving DLQI MCID and/or DLQI 0/1 compared with placebo
- Reduction in impairment while working and in daily activities, as ass by WPAI, were improved in the CZP treatment groups at Week 16 compared with placebo
- Congress with paceboo Improvements in DLOI and WPAI were generally maintained through Week 48 in all C2P maintenance groups DLQI 0/1 responder rates were maintained or improved throughout the Maintenance Treatment Period
- Improvement in DLQI 0/1 responder rate and WPAI domains was most pronounced in the group that received CZP 400 mg Q2W in both the Initial and Maintenance Periods
- These results indicate that longer-term treatment with CZP has a positive impact on patient quality of life and functioning
- Given the substantial burden of disease experienced by patients with psoriasis CZP has the potential to be an important new treatment option for patients with moderate-to-severe chronic plaque psoriasis

References

1. Rachakonda et al. J Am Acad Dermatol. 2014;70(3):512-6. 2. Kurd et al. J Am Acad Dermatol. 2009;60(2):218-24. 3. Danielsen et al. Br./ Dermatol: 2013;169(6);130:10. 4. Farber et al. Dermatologica: 1974;148(1);1-18. 6. Langiey et al. Ann Rheum Dis. 2005;64 Suppl 21/18-23. 6. Armstrong et al. PLoS One. 2012;7(12):e52335. 7. Basra et al. Dermatologi 2015/230/11/27-33. 8. All et al. Br J Dermatol. 2017;176/3):577-93. 9. Gottlieb et al. Oral presentation at: 75th Annual Meeting of the American Academy of Dermatology, March 3-7, 2017; Orlando, FL. Abstract 5077: 10. Lebwohl et al. Poster presentation at: 13th Annual Maui Derm for Dermatologists; March 20-24, 2017; Maui, HI. Abstract

Acknowledgements

This study and all costs associated with the development of this poster were funded by Dermira, Inc. Dermira and UCB are in a strategic collaboration to evaluate the efficacy and safety of certolizumab pegol in the treatment of a plaque psoriasis. Medical writing support (Chicago, IL).

Author Disclosures

P: Consulting honoraria and/or speaker fees: AbbV/le, Almirall, Celgene, Jan Department: Abdyle, Ahmiall, Allance, Biensdorf UK List, Bioket, Cageliyon, Demail, Bi Lisy, Gateema, Jopen Fhama, Globalkon, Janssen-Celeg, Lafoche-Posey, L'Olea LL EO Pharma, Meda, MSO, Novaria, Pitzer, Samuned, Sindiar Pharma, Spirt, Steld, Tomton Ross, TyiPhanu, UCB AB: Consulting and/or honoratic Abdyle, Amgen, Boehinger Paghelim, Calgene, Demina, Inc., Genreten, Januare, El Ling, March, Novaria, Pitzer, Represon, Sandoz, DB, JO: Employees of Dermira, Inc. LP, RR: Employees of UCB BioSciences, Inc. JW: Investigator and/or speaker: Amger

Poster presented at the 36th Fall Clinical Dermatology Conference | Las Vegas, NV | October 12-15, 2017